## **PARKING**

Parking validation tickets will be provided for the garage next to the venue.

## **REGISTRATION**

\$100 for MD; \$75 for PA; \$75 for Pharmacist; \$75 for Other **Residents, Nurses and Nurse Practitioners Free** http://conferences.utk.edu/hepatology2020/index.html

## **CANCELLATION**

Written cancellations sent to aherbers@uthsc.edu or UTHSC CME, 920 Madison Ave., Memphis, TN, 38163, must be received by April 5, 2020 to receive a refund of meeting registration fees minus a \$25 administrative fee. Written cancellations received after April 5, 2020 will not receive a refund.

## **ACCREDITATION**

The University of Tennessee College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## **CREDIT**

The University of Tennessee College of Medicine designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### **DISCLOSURE STATEMENT**

The University of Tennessee College of Medicine is committed to providing CME that is balanced, objective, and evidence-based. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Essentials and Standards, all parties involved in content development are required to disclose any real or apparent conflicts of interest relating to the topics of this educational activity. The University of Tennessee has established mechanisms to resolve conflicts of interest should they arrive. Any potential conflict of interest or off label use will be disclosed to the audience prior to the activity.

Non-Profit Org.

U S POSTAGE
PAID

Memphis, TN
Permit No. 1180

4TH ANNUAL **CURRENT PERSPECTIVES IN** HEPATOLOGY (CPH) A Single Theme Symposium on Advanced Liver Disease Saturday, April 25, 2020 8:00 AM - 1:30 PM FedEx Institute of Technology, The Zone University of Memphis • 365 Innovation Dr. Memphis, TN 38152 THE UNIVERSITY OF

Office of Continuing Medical Educa 920 Madison Avenue Suite 447 Memphis, TN 38163

## 4TH ANNUAL

# CURRENT PERSPECTIVES IN HEPATOLOGY (CPH)

A Single Theme Symposium on **ADVANCED LIVER DISEASE** 

#### **Course Director**

#### Satheesh Nair, MD., AGAF, FAASLD

Professor of Medicine Medical Director Liver Transplantation University of Tennessee Health Science Center MUH James D. Eason Transplant Institute

#### **Course Co-Directors**

#### Benedict J. Maliakkal, MD

Associate Professor of Medicine Division of Transplant Surgery University of Tennessee Health Science Center MUH James D. Eason Transplant Institute

#### James D. Eason, MD

Director Transplant Institute
Chief of Transplant
Professor of Surgery
University of Tennessee Health Science Center
MUH James D. Eason Transplant Institute

## **UTHSC Faculty - MUH Transplant Institute**

Dr. Uchenna Agbim, MD - Assistant Professor

Dr. Jiten Kothadia, MD - Assistant Professor


Dr. Corey Eymard, MD - Assistant Professor

**Dr. Daniel Maluf, MD -** Professor of Surgery, Surgical Director of Liver Transplantation

## **Learning Objectives**

- 1. Best practices in treating complications of cirrhosis such as HCC, HRS, Ascites, Varices, Hepatic encephalopathy
- 2. Treatment of viral hepatitis, NASH, PBC
- 3. Risks and benefits of drugs in patients with cirrhosis
- 4. Recent advances in Transplant

## **GUEST FACULTY**



#### Jennifer C. Lai, MD, MBA

Dr. Lai is a transplant hepatologist, Associate Professor In Residence at the University of California, San Francisco and Director of the UCSF Hepatology Clinical Research Group. Her long-term mission is to help patients with end-stage liver disease survive and thrive after liver transplantation.



#### Mark Russo, MD

Dr. Russo is Chief of Hepatology and Medical Director of Liver Transplantation at Carolinas Medical Center, Atrium Health, Charlotte. He is a fellow in the AASLD, AGA, ACG, a member of the nominating committee of the AASLD, on the board of the ACG Institute and has published more than 100 articles.



#### Mitchell L Shiffman, MD

Dr Shiffman is the Director of the Liver Institute of Virginia at Bon Secours Mercy Health with offices in Richmond and Newport News, VA. He has published over 250 peer reviewed manuscripts, review articles and/or book chapters on various topics in liver disease and has edited 3 textbooks. He lectures frequently on various liver disease topics at national and international meetings and board review courses.



#### Tamar Taddei, MD

Dr. Taddei, MD, is Associate Professor of Medicine in the Section of Digestive Diseases at Yale University and staff hepatologist at the VA Connecticut Healthcare System in West Haven, CT. She directs the liver cancer program at VA Connecticut. She leads the VA Connecticut's Cancer Care Tracking System Team, a group that has facilitated early detection of cancer and timely access to comprehensive cancer care through innovation in systems of care and technology.

## MEETING AGENDA Saturday, April 25, 2020

# SESSION I Complications of Cirrhosis Moderators: Nair/Kothadia

8:00-8:15	Welcome Satheesh Nair
8:15-8:45	Variceal Bleeding; Best Practices Mark Russo
8:45-9:15	New Mass in a Cirrhotic Liver Tamar Taddei
9:15-9:45	<b>Ascites Optimizing Diuretic Therapy</b> Ben Maliakkal
9:45-10:15	Acute Decompensation of Cirrhotic Liver: Definitions, Risk Predictions and Management Jennifer Lai
10:15-10:30	Break
10:30-11:15	Case Studies: Encephalopathy, HPS, Obscure bleeding, PVT Agbim, Russo, Lai, Taddei, Shiffman

#### SESSION 2

Liver Transplantation, Moderators

Moderators: Maluf/Eason

	7410 de l'altere 1013. 141 di 01/ Ed3011
11:15-11:35	<b>When to Refer a Patient for Transplant</b> Mitchell Shiffman
11:35-11:55	<b>Minimizing Wait Time for Liver Transplantation</b> Corey Eymard
11:55-12:00	Q&A
12:00-12:15	Boxed Lunch

# SESSION 3 Drugs and Cirrhosis

Moderators: Nair/Agbim

12:15-12:45	<b>Liver Targeted Drugs in Patients with Cirrhosis</b> Mitchell Shiffman
12:45-1:15	<b>Non Liver Drugs and Potential Benefits in Cirrhosis</b> Mark Russo
1:15-1:30	Q&A, Closing Remarks